Hubei Goto Biopharm Group Co., Ltd. Class A

Hubei Goto Biopharm Group Co., Ltd. Class A

SSZSE:300966
23.32
CNY
-0.48
(-2.02%)
-0.89EPS
2.96BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.25
5.2
5.41
5.45
5.59
5.26
4.92
4.67
5.29
5.93
Basic EPS, GAAP
1.03
0.84
0.85
0.62
0.74
0.35
0.2
-0.24
-0.64
-0.8
Free Cash Flow per Basic Share
-0.91
-0.73
-0.29
-0.06
-0.31
-3.76
-2.97
-2.89
-1.09
- -
Dividend per Share
0.07
0.05
0.11
0.11
0.07
0.23
0.05
0.22
0.26
0.27
Book Value per Share
3.48
4.73
5.58
6.2
7
8.05
8.26
8.01
7.17
6.73
Tangible Book Value per Share
3.32
4.58
5.33
5.95
6.76
7.68
7.82
7.58
6.7
6.27
Basic Weighted Avg Shares
46
84
86
86
106
115
115
115
115
112
Sales/Revenue/Turnover
334
437
465
468
591
605
566
537
606
666
Operating Margin (%)
18.58
19.82
19.98
14.08
12.26
8.75
7.37
-0.39
-5.54
-7.25
Depreciation Expense
10
15
17
21
23
27
28
43
115
- -
Net Income, GAAP
47
71
73
53
78
40
23
-28
-73
-90
Effective Tax Rate (%)
14.74
12.08
11.85
11.7
9.35
- -
- -
- -
- -
- -
Profit Margin (%)
14.22
16.16
15.7
11.38
13.26
6.65
4.06
-5.14
-12.1
-13.47
Working Capital
123
239
291
332
525
638
183
-38
-52
39
LT Debt
- -
- -
- -
1
7
441
653
813
974
1,042
Total Equity
300
408
481
540
828
981
1,024
1,015
909
852
Return on Invested Capital (%)
- -
17.12
13.31
8.08
6.87
- -
- -
- -
- -
- -
Return on Capital (%)
- -
21.7
16.74
9.97
9.97
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
19.95
16.41
10.49
11.68
4.63
2.45
-2.94
-8.39
-10.65

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
319
343
320
LT Borrowings
999
979
1,041
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
115
115
115
Market Capitalization
2,430
3,171
2,963

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
825
837
913
Cash, Cash Equivalents & STI
75
76
108
Accounts Receivable, Net
189
222
209
Inventories
487
497
536
Total Current Liabilities
833
902
873
Payables & Accruals
- -
- -
- -
ST Debt
319
343
320
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.99%
-10.38%
Free Cash Flow
- -
334.75%
-62.29%
Net Income, GAAP
- -
-19.7%
165.88%
Sales/Revenue/Turnover
- -
5.99%
12.97%
Total Cash Common Dividend
- -
99.65%
16.11%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
122
112
132
171
537
2025
139
163
- -
151
606
2026
162
184
168
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
-0.08
-0.08
-0.12
-0.24
2025
0.01
-0.11
- -
-0.36
-0.64
2026
0.03
-0.32
-0.14
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.04
0.04
0.11
0.22
2025
0.03
0.06
- -
0.12
0.26
2026
0.05
0.06
0.03
- -
- -

Company Description

CEO
Zu Bin Xi
Full Time Employees
893
Sector
Health technology
Industry
Biotechnology
Address
Building 1, Global Financial City Xiangyang HB China 441057
IPO Date
Apr 9, 2021
Business
Hubei Goto Biopharm Co.,Ltd. specializes in the research, development, production, and global distribution of steroidal pharmaceutical raw materials and intermediates. The company provides essential starting compounds, including 9a-hydroxy-4-androstenedione (9a-OHAD), bisnoralcohol (BA), 1,4-androstadienedione (ADD), and 4-androstenedione (4-AD), derived from plant sterols through advanced bioconversion. Its offerings further extend to various intermediates, such as those for sex hormones, progesterone, and corticosteroids, alongside other active pharmaceutical ingredients. Established in 2006, the high-tech enterprise maintains its primary operations in Yicheng, China, and was listed on the GEM of the Shenzhen Stock Exchange in April 2021. The firm is recognized as a significant supplier in the steroid drug intermediate sector, emphasizing its comprehensive product chain and robust R&D capabilities in molecular biology, enzyme engineering, and chemical synthesis.